Stay updated on Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the study of fruquintinib combined with tislelizumab is displayed, with study information and results-related details. It indicates the study is terminated and no longer recruiting participants.
    Difference
    67%
    Check dated 2026-11-09T13:50:17.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the page remains a 403 Forbidden error screen.
    Difference
    0.2%
    Check dated 2026-11-02T15:43:14.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH updates and says some content may use “Super Intelligence” (SI) instead of “Artificial Intelligence” (AI) during a transition.
    Difference
    1%
    Check dated 2026-10-26T14:33:20.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changes from v3.7.1 to v3.7.2. The page still displays a 403 Forbidden error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-19T14:15:22.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-12T14:52:03.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study content and navigation with a minimal header. This indicates the record is currently inaccessible due to access restrictions.
    Difference
    20%
    Check dated 2026-09-21T22:21:58.000Z thumbnail image

Stay in the know with updates to Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.